gastric%20cancer
GASTRIC CANCER
Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.
  1. Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(5):531-546. Accessed 28 Jan 2014. PMID: 23667204
  2. Waddell T, Verheji M, Allum W, et al. Gastric cancer: ESMO-ESSO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi57-vi63. doi: 10.1093/annonc/mdt344. Accessed 28 Jan 2014. PMID: 24078663
  3. American Cancer Society. Stomach Cancer. American Cancer Society. http://www.cancer.org/.
  4. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: gastric cancer (including cancer in the proximal 5 cm of the stomach) version 2.2013. National Comprehensive Cancer Network. http://www.nccn.org/.
  5. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: gastric cancer version 1.2014. National Comprehensive Cancer Network. http://www.nccn.org/.
  6. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101-112. doi: 10.1007/s1020-011-0041-5. Accessed 9 Sep 2014. PMID: 21573743
  7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer version 1.2015. NCCN web site. http://www.nccn.org/. 08 Jan 2015. Accessed 18 Feb 2015.
  8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer version 3.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Aug 2016.
  9. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(Suppl 5):v38-v49. https://annonc.oxfordjournals.org/. Accessed 03 Nov 2016. PMID: 27664260
  10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer version 3.2015. NCCN. http://www.nccn.org/. 23 Mar 2015. Accessed 31 Mar 2016.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.